drugset / Trial / NCT00401973

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

NCT00401973

Phase 3 Completed 199 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelPrevention

Summary

The goal of this study is to answer the following questions: * Whether treatment with amantadine, metformin or zonisamide can prevent or reverse the weight gain that is associated with olanzapine * Whether taking amantadine, metformin or zonisamide can help patients decrease or eliminate some of the changes in body that occur with weight gain * How weight gain associated with olanzapine can affect people * Whether treatment with amantadine, metformin or zonisamide can help eliminate weight gain associated with olanzapine and not interfere with the positive effects of olanzapine on functioning of people with schizophrenia and other diseases

Timeline

Start
2006-11
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Amantadine Unknown 100 mg Oral
Subject Metformin Small molecule 500 mg Oral
Subject Olanzapine Small molecule 5 mg Oral
Subject Olanzapine Small molecule 20 mg Oral
Subject Zonisamide Other / unclassified 100 mg Oral
Subject Zonisamide Other / unclassified 400 mg Oral